FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896978422> ?p ?o ?g. }

• W2896978422 endingPage "1515" @default.
• W2896978422 startingPage "1504" @default.
• W2896978422 abstract "Background The NRG/RTOG 9413 study showed that whole pelvic radiotherapy (WPRT) plus neoadjuvant hormonal therapy (NHT) improved progression-free survival in patients with intermediate-risk or high-risk localised prostate cancer compared with prostate only radiotherapy (PORT) plus NHT, WPRT plus adjuvant hormonal therapy (AHT), and PORT plus AHT. We provide a long-term update after 10 years of follow-up of the primary endpoint (progression-free survival) and report on the late toxicities of treatment. Methods The trial was designed as a 2 × 2 factorial study with hormonal sequencing as one stratification factor and radiation field as the other factor and tested whether NHT improved progression-free survival versus AHT, and NHT plus WPRT versus NHT plus PORT. Eligible patients had histologically confirmed, clinically localised adenocarcinoma of the prostate, an estimated risk of lymph node involvement of more than 15% and a Karnofsky performance status of more than 70, with no age limitations. Patients were randomly assigned (1:1:1:1) by permuted block randomisation to receive either NHT 2 months before and during WPRT followed by a prostate boost to 70 Gy (NHT plus WPRT group), NHT 2 months before and during PORT to 70 Gy (NHT plus PORT group), WPRT followed by 4 months of AHT (WPRT plus AHT group), or PORT followed by 4 months of AHT (PORT plus AHT group). Hormonal therapy was combined androgen suppression, consisting of goserelin acetate 3·6 mg once a month subcutaneously or leuprolide acetate 7·5 mg once a month intramuscularly, and flutamide 250 mg twice a day orally for 4 months. Randomisation was stratified by T stage, Gleason Score, and prostate-specific antigen concentration. NHT was given 2 months before radiotherapy and was continued until radiotherapy completion; AHT was given at the completion of radiotherapy for 4 months. The primary endpoint progression-free survival was analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769548. The trial has been terminated to additional follow-up collection and this is the final analysis for this trial. Findings Between April 1, 1995, and June 1, 1999, 1322 patients were enrolled from 53 centres and randomly assigned to the four treatment groups. With a median follow-up of 8·8 years (IQR 5·07–13·84) for all patients and 14·8 years (7·18–17·4) for living patients (n=346), progression-free survival across all timepoints continued to differ significantly across the four treatment groups (p=0·002). The 10-year estimates of progression-free survival were 28·4% (95% CI 23·3–33·6) in the NHT plus WPRT group, 23·5% (18·7–28·3) in the NHT plus PORT group, 19·4% (14·9–24·0) in the WPRT plus AHT group, and 30·2% (25·0–35·4) in the PORT plus AHT group. Bladder toxicity was the most common grade 3 or worse late toxicity, affecting 18 (6%) of 316 patients in the NHT plus WPRT group, 17 (5%) of 313 in the NHT plus PORT group, 22 (7%) of 317 in the WPRT plus AHT group, and 14 (4%) of 315 in the PORT plus AHT group. Late grade 3 or worse gastrointestinal adverse events occurred in 22 (7%) of 316 patients in the NHT plus WPRT group, five (2%) of 313 in the NHT plus PORT group, ten (3%) of 317 in the WPRT plus AHT group, and seven (2%) of 315 in the PORT plus AHT group. Interpretation In this cohort of patients with intermediate-risk and high-risk localised prostate cancer, NHT plus WPRT improved progression-free survival compared with NHT plus PORT and WPRT plus AHT at long-term follow-up albeit increased risk of grade 3 or worse intestinal toxicity. Interactions between radiotherapy and hormonal therapy suggests that WPRT should be avoided without NHT. Funding National Cancer Institute." @default.
• W2896978422 created "2018-10-26" @default.
• W2896978422 creator A5000658342 @default.
• W2896978422 creator A5002244293 @default.
• W2896978422 creator A5012866369 @default.
• W2896978422 creator A5019525982 @default.
• W2896978422 creator A5026550142 @default.
• W2896978422 creator A5026765121 @default.
• W2896978422 creator A5031160818 @default.
• W2896978422 creator A5038819739 @default.
• W2896978422 creator A5039395742 @default.
• W2896978422 creator A5039437100 @default.
• W2896978422 creator A5042728664 @default.
• W2896978422 creator A5045162411 @default.
• W2896978422 creator A5049018134 @default.
• W2896978422 creator A5049646055 @default.
• W2896978422 creator A5052233371 @default.
• W2896978422 creator A5052573263 @default.
• W2896978422 creator A5059609929 @default.
• W2896978422 creator A5060238737 @default.
• W2896978422 creator A5060545257 @default.
• W2896978422 creator A5078153183 @default.
• W2896978422 creator A5084926889 @default.
• W2896978422 creator A5089472018 @default.
• W2896978422 creator A5091279526 @default.
• W2896978422 date "2018-11-01" @default.
• W2896978422 modified "2023-10-15" @default.
• W2896978422 title "Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial" @default.
• W2896978422 cites W1602314627 @default.
• W2896978422 cites W1770259999 @default.
• W2896978422 cites W1969315444 @default.
• W2896978422 cites W1969965083 @default.
• W2896978422 cites W2010881564 @default.
• W2896978422 cites W2011197894 @default.
• W2896978422 cites W2021220421 @default.
• W2896978422 cites W2038981426 @default.
• W2896978422 cites W2042146625 @default.
• W2896978422 cites W2043246469 @default.
• W2896978422 cites W2043978545 @default.
• W2896978422 cites W2058148390 @default.
• W2896978422 cites W2073140442 @default.
• W2896978422 cites W2086798071 @default.
• W2896978422 cites W2093867637 @default.
• W2896978422 cites W2108864389 @default.
• W2896978422 cites W2116641263 @default.
• W2896978422 cites W2125224787 @default.
• W2896978422 cites W2131809909 @default.
• W2896978422 cites W2142359566 @default.
• W2896978422 cites W2142629844 @default.
• W2896978422 cites W2144931990 @default.
• W2896978422 cites W2176970460 @default.
• W2896978422 cites W2536173378 @default.
• W2896978422 cites W2673309218 @default.
• W2896978422 cites W2731200312 @default.
• W2896978422 cites W4242589154 @default.
• W2896978422 cites W4293241248 @default.
• W2896978422 doi "https://doi.org/10.1016/s1470-2045(18)30528-x" @default.
• W2896978422 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6540797" @default.
• W2896978422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30316827" @default.
• W2896978422 hasPublicationYear "2018" @default.
• W2896978422 type Work @default.
• W2896978422 sameAs 2896978422 @default.
• W2896978422 citedByCount "151" @default.
• W2896978422 countsByYear W28969784222018 @default.
• W2896978422 countsByYear W28969784222019 @default.
• W2896978422 countsByYear W28969784222020 @default.
• W2896978422 countsByYear W28969784222021 @default.
• W2896978422 countsByYear W28969784222022 @default.
• W2896978422 countsByYear W28969784222023 @default.
• W2896978422 crossrefType "journal-article" @default.
• W2896978422 hasAuthorship W2896978422A5000658342 @default.
• W2896978422 hasAuthorship W2896978422A5002244293 @default.
• W2896978422 hasAuthorship W2896978422A5012866369 @default.
• W2896978422 hasAuthorship W2896978422A5019525982 @default.
• W2896978422 hasAuthorship W2896978422A5026550142 @default.
• W2896978422 hasAuthorship W2896978422A5026765121 @default.
• W2896978422 hasAuthorship W2896978422A5031160818 @default.
• W2896978422 hasAuthorship W2896978422A5038819739 @default.
• W2896978422 hasAuthorship W2896978422A5039395742 @default.
• W2896978422 hasAuthorship W2896978422A5039437100 @default.
• W2896978422 hasAuthorship W2896978422A5042728664 @default.
• W2896978422 hasAuthorship W2896978422A5045162411 @default.
• W2896978422 hasAuthorship W2896978422A5049018134 @default.
• W2896978422 hasAuthorship W2896978422A5049646055 @default.
• W2896978422 hasAuthorship W2896978422A5052233371 @default.
• W2896978422 hasAuthorship W2896978422A5052573263 @default.
• W2896978422 hasAuthorship W2896978422A5059609929 @default.
• W2896978422 hasAuthorship W2896978422A5060238737 @default.
• W2896978422 hasAuthorship W2896978422A5060545257 @default.
• W2896978422 hasAuthorship W2896978422A5078153183 @default.
• W2896978422 hasAuthorship W2896978422A5084926889 @default.
• W2896978422 hasAuthorship W2896978422A5089472018 @default.
• W2896978422 hasAuthorship W2896978422A5091279526 @default.
• W2896978422 hasBestOaLocation W28969784222 @default.
• W2896978422 hasConcept C121608353 @default.
• W2896978422 hasConcept C126322002 @default.
• W2896978422 hasConcept C126894567 @default.
• W2896978422 hasConcept C143998085 @default.

• next